UlkaNitinVaishampayanMD

Oncology • Ann Arbor, MI

Genitourinary Oncology

Director of Phase I at Rogel Cancer Center Professor of medicine/oncology University of Michigan Ann Arbor MI

Join to view full profile

Dr. Vaishampayan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vaishampayan's full profile

Already have an account?

Office
7217 Rogel cancer center
1500 E Medical center dr
Ann Arbor, MI 48109
Phone+1 734-647-8903

Fax+1 734-232-9357

Summary

Dr. Ulka Vaishampayan is an oncologist practicing at University of Michigan Ann Arbor MI. She received her medical degree from B.J. Medical College - University of Pune and has been in practice 24 years. She specializes in medical oncology and is experienced in urologic and general medical oncology. Her research focus is clinical trials and drug development and novel biomarkers in cancer.

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1997 - 2000
Wayne State University School of MedicineResidency, Internal Medicine, 1994 - 1997
B.J. Medical College - University of PuneClass of 1993

Certifications & Licensure

MI State Medical License 1997 - 2026
American Board of Internal Medicine Medical Oncology

Clinical Trials

Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 2
Chemotherapy in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 2
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Start of enrollment: 2002 Nov 01
Completed
Phase 2
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors Start of enrollment: 2005 Mar 01
Completed
Phase 1
PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma Start of enrollment: 2001 Jan 01
Completed
Phase 2
Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2003 Aug 01
Completed
Phase 2
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
Withdrawn
Phase 2
Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel Start of enrollment: 2007 Oct 01
Completed
Not Applicable
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration Start of enrollment: 2009 Jun 01
Completed
Phase 1, Phase 2
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer Start of enrollment: 2009 Sep 01
Suspended
Not Applicable
Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel Start of enrollment: 2010 Feb 01
Completed
Phase 2
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer Start of enrollment: 2010 Apr 01
Completed
Phase 2
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Start of enrollment: 2010 Aug 06
Completed
Phase 2
PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer Start of enrollment: 2010 Sep 01
Completed
Not Applicable
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Start of enrollment: 2011 Sep 06
Completed
Phase 1, Phase 2
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 1
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2011 Oct 01
Completed
Phase 1, Phase 2
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 1
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer Start of enrollment: 2012 Aug 01
Completed
Phase 2
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy Start of enrollment: 2012 Dec 18
Completed
Phase 2
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer Start of enrollment: 2013 Mar 01
Completed
Not Applicable
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone. Start of enrollment: 2015 May 01
Completed
Phase 2
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2016 Aug 01
Terminated
Phase 1, Phase 2
Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2018 Jun 07
Completed
Phase 2
Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo Start of enrollment: 2018 Apr 24
Completed
Phase 2
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer Start of enrollment: 2012 Nov 21
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

55 citations
Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
Amishi Yogesh Shah, Jose A. Karam, Gabriel G. Malouf, Priya Rao, Zita D. Lim
BJU International. 2017-12-01
42 citations
Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder
David Smith, Niklas J. Mackler, Rodney L. Dunn, Maha Hussain, Darien Wood
The Journal of Urology. 2008-12-01
128 citations
First-in-human phase 1 study of the anti–TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non–small cell lung cancer
Jiaxin Niu, Corinne Maurice-Dror, Dongwhane Lee, Dai Woo Kim, Adnan Nagrial
Annals of Oncology. 2021-11-17

Lectures

Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.
2019 ASCO Annual Meeting - 6/1/2019
Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population.
2019 ASCO Annual Meeting - 6/1/2019
A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Personalized Approach to Systemic Therapy of Renal Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
Join now to see all

Press Mentions

Major Bladder Cancer Study Disappoints: “We Won’t Have a Whole Lot of Other Treatment Options”June 3rd, 2024
Rare Disease Day with Thomas Abrams, MD; Maria Badillo, MSN, RN, OCN®, CCRP; And Ulka Vaishampayan, MDMarch 20th, 2023
Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022
Join now to see all